Mr. Todd Shapiro reports

RED LIGHT HOLLAND HIGHLIGHTS PUBLICATION OF RANDOMIZED CLINICAL TRIAL SHOWING A SINGLE DOSE OF PSILOCYBIN REDUCED COCAINE USE, WITH FILAMENT HEALTH HOLDING THE EXCLUSIVE LICENSE TO THE DATA AND INTELLECTUAL PROPERTY

Following its acquisition of Filament Health Corp., Red Light Holland Corp. has expanded its pharmaceutical-grade manufacturing and regulatory and clinical research capabilities, supporting the advancement of naturally derived psilocybin development and Filament's patented botanical drug candidate, PEX010. Red Light and Filament are excited to highlight the publication yesterday of a peer-reviewed randomized clinical trial in JAMA Network Open evaluating a single dose of psilocybin in adults with cocaine use disorder, for which Filament holds the exclusive worldwide licence to the trial's data and certain associated intellectual property pursuant to its June, 2025, agreement with the University of Alabama at Birmingham (UAB).

The trial, "Psilocybin in the Treatment of Cocaine Use Disorder: A Randomized Clinical Trial" (Hendricks P.S., Lappan S.N., Shelton R.C., et al. JAMA Network Open. 2026;9(5):e2611029), reports that participants who received a single dose of psilocybin had a statistically significant and sustained reduction in cocaine use compared with active placebo, with a meaningful subset achieving complete abstinence through six months of follow-up. The full publication, including methods, statistical analyses and limitations, is openly available on-line. Cocaine use disorder is a chronic, relapsing condition for which there are currently no FDA-approved (U.S. Food and Drug Administration) pharmacotherapies.

The psilocybin used in the published trial was a synthetic compound and was not Filament's botanical drug candidate, PEX010; the licensed data and intellectual property are intended to support Filament's continuing development of PEX010 for stimulant use disorder.

Filament's development program in stimulant use disorder is well advanced. Filament's lead botanical psilocybin drug candidate, PEX010, has received phase 2 clinical trial authorization in stimulant use disorder from both the U.S. Food and Drug Administration and Health Canada, providing a clear regulatory path to translate these findings into a development program for PEX010. The data licensed from UAB are intended to inform and accelerate Filament's regulatory and clinical strategy for PEX010 in this indication.

Todd Shapiro, chief executive officer and director of Red Light, commented: "This is exactly the kind of science we set out to be associated with when we acquired Filament. Dr. Hendricks and his team have produced the first randomized data showing that a single dose of psilocybin can help people with cocaine use disorder, a population that has been waiting decades for a treatment that works, and one that has been largely overlooked by the rest of the field. We are proud that Filament holds the exclusive worldwide licence to this dataset, and we believe it provides a strong foundation for advancing PEX010, our patented natural psilocybin drug candidate, through Filament's authorized phase 2 program in stimulant use disorder. There is real work ahead, and these results need to be replicated in larger trials, but today is a meaningful day for patients, for science and for our company."

Dr. Peter S. Hendricks, lead investigator of the trial and professor in the department of psychiatry and behavioural neurobiology at the University of Alabama at Birmingham, added: "Cocaine use disorder is a chronic, relapsing condition with no FDA-approved pharmacotherapies, and the people most affected are too often left out of clinical research. The findings published today suggest that a single dose of psilocybin may help individuals with cocaine use disorder reduce their use, with a meaningful subset achieving complete abstinence sustained through six months. These results are promising but preliminary, and adequately powered confirmatory trials are essential next steps."

Benjamin Lightburn, chief executive officer of Filament Health, added: "We entered into our licensing agreement with UAB in 2025 specifically because we believed Dr. Hendricks's work could help unlock a development pathway for PEX010 in one of medicine's most underserved areas. With this peer-reviewed publication now in hand, and with FDA and Health Canada authorization already secured for our phase 2 stimulant use disorder program, we are well positioned to advance PEX010 with discipline and urgency."

About Red Light Holland Corp.

Red Light Holland is an Ontario-based organization advancing a focused strategy within the legal psychedelic sector, centred on consensual data collection and R&D (research and development) initiatives designed to expand naturally occurring drug development, understanding of psilocybin use and consumer experiences. Following the closing of the acquisition of Filament Health, Filament is now a wholly owned subsidiary of the company, bringing together its established good manufacturing practice (GMP) production capabilities, regulatory engagement with the U.S. Food and Drug Administration (FDA), and a growing global clinical footprint anchored by PEX010, a patented botanical psilocybin drug candidate. In parallel, the company operates commercial activities across Europe and North America, including psilocybin truffle sales in the Netherlands' legal market and mushroom home grow kits offered through B2B (business-to-business) and DTC (direct-to-consumer) channels, in compliance with applicable laws.

About Filament Health Corp.

Filament Health is a clinical-stage natural psychedelic drug development company and a wholly owned subsidiary of Red Light Holland.

We seek Safe Harbor.